Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
General cellular and extracellular matrix (ECM) components encompass the complex network of proteins, such as collagens and elastins, and polysaccharides that provide structural and biochemical support to cells (Frantz et al., 2010, J Cell Sci). This category is not a single therapeutic target but a broad biological compartment essential for tissue integrity, cell signaling, and homeostasis (Lu et al., 2012, J Cell Biol). In diseases like cancer, the ECM is often remodeled to promote tumor invasion and chemoresistance, while in fibrotic diseases, it becomes excessively stiff and accumulated (Winkler et al., 2020, Nat Commun). Pharmacological interventions typically target specific ECM constituents or their receptors, such as integrins or matrix metalloproteinases, rather than the matrix as a whole (Naba et al., 2016, BMC Cancer). Consequently, this term is considered a descriptive category or a biological environment rather than a specific, druggable molecular entity.
Enzymatic degradation of matrix components, inhibition of cell-adhesion receptors (integrins), or modulation of matrix cross-linking and synthesis.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on General cellular and extracellular matrix components.